Revolution Medicines drug RMC-6236 increased progression-free survival in patients with advanced cases of pancreatic ductal adenocarcinoma. With these results, the biotech is preparing for a Phase 3 clinical trial in this indication, the most common type of pancreatic cancer.
Researchers at the University of Texas MD Anderson Cancer Center published two studies this week on a new approach that could improve treatment for patients with pancreatic cancer. The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Although they're still early, the company presented Phase Ib/II study data showing its PLK1 inhibitor, onvasertib, was able to produce responses in KRAS-mutated metastatic CRC, through a property known as synthetic lethality. KRAS-specific drugs have shown low efficacy in mCRC.
The companies said Monday that they would partner to develop small-molecule oncology drugs against several targets, including KRAS mutations, long thought "undruggable." Amgen and Mirati have already presented clinical data from their KRAS programs.
An analyst noted that Mirati's MRTX849, a KRAS G12C inhibitor, is six to nine months behind Amgen's AMG 510, but that the market has room for both. The data presented were on patients with lung and colorectal cancers.
The biotech company presented data for AMG 510 at the European Society for Medical Oncology during the weekend. Although the drug showed activity, the data got mixed reactions from investment bank analysts.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
The company said in its earnings statement that AMG 510 had produced objective responses in patients with colorectal and appendiceal cancers. The Phase II portion of the Phase I/II study, which may be used for registration, will start enrolling in the coming days.
The company is targeting pathways such as SHP2 and KRAS G12C. RAS mutations have been an attractive target in oncology due to the central role they play in cancers.
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.